| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | -0.071 | 0.03 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.11 | 0.03 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.03 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.083 | 0.03 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.03 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.067 | 0.03 |
| mRNA | Midostaurin | GDSC1000 | pan-cancer | AAC | -0.071 | 0.03 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.081 | 0.04 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.079 | 0.04 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.078 | 0.04 |